{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:48:22Z","timestamp":1760147302663,"version":"build-2065373602"},"reference-count":60,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T00:00:00Z","timestamp":1674604800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Gilead Sciences (United Kingdom)","award":["IN-IT-540-6233"],"award-info":[{"award-number":["IN-IT-540-6233"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Microorganisms"],"abstract":"<jats:p>There are still conflicting data on the virological effects of the SARS-CoV-2 direct antivirals used in clinical practice, in spite of the documented clinical efficacy. The aim of this monocentric retrospective study was to compare virologic and laboratory data of patients admitted due to SARS-CoV-2 infection from March to December 2020 treated with either remdesivir (R), a protease inhibitor (lopinavir or darunavir\/ritonavir (PI)) or no direct antiviral drugs (NT). Viral load variation was indirectly assessed through PCR cycle threshold (Ct) values on the nasopharyngeal swab, analyzing the results from swabs obtained at ward admission and 7 (\u00b12) days later. Overall, 253 patients were included: patients in the R group were significantly older, more frequently males with a significantly higher percentage of severe COVID-19, requiring more often intensive care admission, compared to the other groups. Ct variation over time did not differ amongst the three treatment groups and did not seem to be influenced by corticosteroid use, even after normalization of the treatment groups for disease severity. Non-survivors had lower Ct on admission and showed a significantly slower viral clearance compared to survivors. CD4 T-lymphocytes absolute count assessed at ward admission correlated with a reduced Ct variation over time. In conclusion, viral clearance appears to be slower in COVID-19 non-survivors, while it seems not to be influenced by the antiviral treatment received.<\/jats:p>","DOI":"10.3390\/microorganisms11020312","type":"journal-article","created":{"date-parts":[[2023,1,26]],"date-time":"2023-01-26T01:57:07Z","timestamp":1674698227000},"page":"312","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Remdesivir Influence on SARS-CoV-2 RNA Viral Load Kinetics in Nasopharyngeal Swab Specimens of COVID-19 Hospitalized Patients: A Real-Life Experience"],"prefix":"10.3390","volume":"11","author":[{"given":"Laura","family":"Campogiani","sequence":"first","affiliation":[{"name":"Department of System Medicine, Tor Vergata University, 00133 Rome, Italy"},{"name":"Infectious Disease Clinic, Policlinico Tor Vergata, 00133 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6938-8627","authenticated-orcid":false,"given":"Marco","family":"Iannetta","sequence":"additional","affiliation":[{"name":"Department of System Medicine, Tor Vergata University, 00133 Rome, Italy"},{"name":"Infectious Disease Clinic, Policlinico Tor Vergata, 00133 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Di Lorenzo","sequence":"additional","affiliation":[{"name":"Department of System Medicine, Tor Vergata University, 00133 Rome, Italy"},{"name":"Infectious Disease Clinic, Policlinico Tor Vergata, 00133 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Zordan","sequence":"additional","affiliation":[{"name":"Department of System Medicine, Tor Vergata University, 00133 Rome, Italy"},{"name":"Infectious Disease Clinic, Policlinico Tor Vergata, 00133 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pier Giorgio","family":"Pace","sequence":"additional","affiliation":[{"name":"Department of System Medicine, Tor Vergata University, 00133 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Coppola","sequence":"additional","affiliation":[{"name":"Department of System Medicine, Tor Vergata University, 00133 Rome, Italy"},{"name":"Infectious Disease Clinic, Policlinico Tor Vergata, 00133 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6372-5434","authenticated-orcid":false,"given":"Mirko","family":"Compagno","sequence":"additional","affiliation":[{"name":"Department of System Medicine, Tor Vergata University, 00133 Rome, Italy"},{"name":"Infectious Disease Clinic, Policlinico Tor Vergata, 00133 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Malagnino","sequence":"additional","affiliation":[{"name":"Department of System Medicine, Tor Vergata University, 00133 Rome, Italy"},{"name":"Infectious Disease Clinic, Policlinico Tor Vergata, 00133 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabetta","family":"Teti","sequence":"additional","affiliation":[{"name":"Department of System Medicine, Tor Vergata University, 00133 Rome, Italy"},{"name":"Infectious Disease Clinic, Policlinico Tor Vergata, 00133 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Andreoni","sequence":"additional","affiliation":[{"name":"Department of System Medicine, Tor Vergata University, 00133 Rome, Italy"},{"name":"Infectious Disease Clinic, Policlinico Tor Vergata, 00133 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1452-0333","authenticated-orcid":false,"given":"Loredana","family":"Sarmati","sequence":"additional","affiliation":[{"name":"Department of System Medicine, Tor Vergata University, 00133 Rome, Italy"},{"name":"Infectious Disease Clinic, Policlinico Tor Vergata, 00133 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,1,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1056\/NEJMoa2001316","article-title":"Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia","volume":"382","author":"Li","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"105948","DOI":"10.1016\/j.ijantimicag.2020.105948","article-title":"Review of the 2019 Novel Coronavirus (SARS-CoV-2) Based on Current Evidence","volume":"55","author":"Wang","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical Course and Risk Factors for Mortality of Adult Inpatients with COVID-19 in Wuhan, China: A Retrospective Cohort Study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e00512-20","DOI":"10.1128\/JCM.00512-20","article-title":"Laboratory Diagnosis of COVID-19: Current Issues and Challenges","volume":"58","author":"Tang","year":"2020","journal-title":"J. Clin. Microbiol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s40121-020-00324-3","article-title":"A Systematic Review of the Clinical Utility of Cycle Threshold Values in the Context of COVID-19","volume":"9","author":"Rao","year":"2020","journal-title":"Infect. Dis. Ther."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"ofac463","DOI":"10.1093\/ofid\/ofac463","article-title":"Correlation of SARS-CoV-2 Nasopharyngeal CT Values With Viremia and Mortality in Adults Hospitalized With COVID-19","volume":"9","author":"Hagman","year":"2022","journal-title":"Open Forum Infect. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1007\/s15010-022-01783-1","article-title":"A Simple Risk Score for Mortality Including the PCR Ct Value upon Admission in Patients Hospitalized Due to COVID-19","volume":"50","author":"Kurzeder","year":"2022","journal-title":"Infection"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"03000605221137443","DOI":"10.1177\/03000605221137443","article-title":"Is SARS-CoV-2 Viral Load a Predictor of Mortality in COVID-19 Acute Respiratory Distress Syndrome Patients?","volume":"50","author":"Dogan","year":"2022","journal-title":"J. Int. Med. Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/cpt.2223","article-title":"Systematic Review and Patient-Level Meta-Analysis of SARS-CoV-2 Viral Dynamics to Model Response to Antiviral Therapies","volume":"110","author":"Gastine","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1007\/s43440-020-00155-6","article-title":"Drug Repurposing Approach to Fight COVID-19","volume":"72","author":"Singh","year":"2020","journal-title":"Pharmacol. Rep."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"6785","DOI":"10.1074\/jbc.RA120.013679","article-title":"Remdesivir Is a Direct-Acting Antiviral That Inhibits RNA-Dependent RNA Polymerase from Severe Acute Respiratory Syndrome Coronavirus 2 with High Potency","volume":"295","author":"Gordon","year":"2020","journal-title":"J. Biol. Chem."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and Chloroquine Effectively Inhibit the Recently Emerged Novel Coronavirus (2019-NCoV) In Vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the Treatment of Covid-19\u2014Final Report","volume":"383","author":"Beigel","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1056\/NEJMoa2116846","article-title":"Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients","volume":"386","author":"Gottlieb","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_15","first-page":"222","article-title":"ESCMID COVID-19 Living Guidelines: Drug Treatment and Clinical Management","volume":"28","author":"Bartoletti","year":"2022","journal-title":"Clin. Microbiol. Infect. Off. Publ. Eur. Soc. Clin. Microbiol. Infect. Dis."},{"key":"ref_16","unstructured":"(2022). Update to Living WHO Guideline on Drugs for Covid-19. BMJ, 378, o1713."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Bhimraj, A., Morgan, R.L., Shumaker, A.H., Lavergne, V., Baden, L., Cheng, V.C.-C., Edwards, K.M., Gandhi, R., Muller, W.J., and O\u2019Horo, J.C. (2020). Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am., ciaa478.","DOI":"10.1093\/cid\/ciaa478"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"m2980","DOI":"10.1136\/bmj.m2980","article-title":"Drug Treatments for Covid-19: Living Systematic Review and Network Meta-Analysis","volume":"370","author":"Siemieniuk","year":"2020","journal-title":"BMJ"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"(2022). Remdesivir and Three Other Drugs for Hospitalised Patients with COVID-19: Final Results of the WHO Solidarity Randomised Trial and Updated Meta-Analyses. Lancet, 399, 1941\u20131953.","DOI":"10.1016\/S0140-6736(22)00519-0"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Russo, P., Tacconelli, E., Olimpieri, P.P., Celant, S., Colatrella, A., Tomassini, L., and Pal\u00f9, G. (2022). Mortality in SARS-CoV-2 Hospitalized Patients Treated with Remdesivir: A Nationwide, Registry-Based Study in Italy. Viruses, 14.","DOI":"10.3390\/v14061197"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1093\/cid\/ciab698","article-title":"Remdesivir and Mortality in Patients With Coronavirus Disease 2019","volume":"74","author":"Diaz","year":"2022","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","article-title":"Remdesivir in Adults with Severe COVID-19: A Randomised, Double-Blind, Placebo-Controlled, Multicentre Trial","volume":"395","author":"Wang","year":"2020","journal-title":"Lancet Lond. Engl."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"WHO Solidarity Trial Consortium, Pan, H., Peto, R., Henao-Restrepo, A.-M., Preziosi, M.-P., Sathiyamoorthy, V., Abdool Karim, Q., Alejandria, M.M., Hern\u00e1ndez Garc\u00eda, C., and Kieny, M.-P. (2021). Repurposed Antiviral Drugs for Covid-19\u2014Interim WHO Solidarity Trial Results. N. Engl. J. Med., 384, 497\u2013511.","DOI":"10.1056\/NEJMoa2023184"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1186\/s13054-020-03398-0","article-title":"Viral RNA Load in Plasma Is Associated with Critical Illness and a Dysregulated Host Response in COVID-19","volume":"24","author":"Almansa","year":"2020","journal-title":"Crit. Care"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"ofab153","DOI":"10.1093\/ofid\/ofab153","article-title":"Viral Load Kinetics of Severe Acute Respiratory Syndrome Coronavirus 2 in Hospitalized Individuals With Coronavirus Disease 2019","volume":"8","author":"Regan","year":"2021","journal-title":"Open Forum Infect. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1002\/jmv.27598","article-title":"CSS-COVID-19 Group Remdesivir Significantly Reduces SARS-CoV-2 Viral Load on Nasopharyngeal Swabs in Hospitalized Patients with COVID-19: A Retrospective Case-Control Study","volume":"94","author":"Biancofiore","year":"2022","journal-title":"J. Med. Virol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.3346\/jkms.2021.36.e83","article-title":"Clinical and Virologic Effectiveness of Remdesivir Treatment for Severe Coronavirus Disease 2019 (COVID-19) in Korea: A Nationwide Multicenter Retrospective Cohort Study","volume":"36","author":"Joo","year":"2021","journal-title":"J. Korean Med. Sci."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"917.e1","DOI":"10.1016\/j.cmi.2021.02.029","article-title":"A Real-Life Setting Evaluation of the Effect of Remdesivir on Viral Load in COVID-19 Patients Admitted to a Large Tertiary Centre in Israel","volume":"27","author":"Goldberg","year":"2021","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","article-title":"A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19","volume":"382","author":"Cao","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"210171","DOI":"10.1183\/16000617.0171-2021","article-title":"The Impact of Therapeutics on Mortality in Hospitalised Patients with COVID-19: Systematic Review and Meta-Analyses Informing the European Respiratory Society Living Guideline","volume":"30","author":"Crichton","year":"2021","journal-title":"Eur. Respir. Rev."},{"key":"ref_31","unstructured":"(2022, February 26). Living Guidance for Clinical Management of COVID-19. Available online: https:\/\/www.who.int\/publications-detail-redirect\/WHO-2019-nCoV-clinical-2021\u20132."},{"key":"ref_32","first-page":"CD014962","article-title":"Remdesivir for the Treatment of COVID-19","volume":"8","author":"Ansems","year":"2021","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Juul, S., Nielsen, E.E., Feinberg, J., Siddiqui, F., J\u00f8rgensen, C.K., Barot, E., Holgersson, J., Nielsen, N., Bentzer, P., and Veroniki, A.A. (2021). Interventions for Treatment of COVID-19: Second Edition of a Living Systematic Review with Meta-Analyses and Trial Sequential Analyses (The LIVING Project). PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0248132"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e403","DOI":"10.1093\/cid\/ciac014","article-title":"Remdesivir plus Dexamethasone versus Dexamethasone Alone for the Treatment of COVID-19 Patients Requiring Supplemental O2 Therapy: A Prospective Controlled Non-Randomized Study","volume":"75","author":"Marrone","year":"2022","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e2015100","DOI":"10.1001\/jamanetworkopen.2020.15100","article-title":"Characteristics of the Multiplicity of Randomized Clinical Trials for Coronavirus Disease 2019 Launched During the Pandemic","volume":"3","author":"Kouzy","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1093\/cid\/ciab631","article-title":"Clinical Improvement, Outcomes, Antiviral Activity, and Costs Associated with Early Treatment with Remdesivir for Patients with COVID-19","volume":"74","author":"Wong","year":"2021","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.7326\/M21-0653","article-title":"Evaluation of the Effects of Remdesivir and Hydroxychloroquine on Viral Clearance in COVID-19","volume":"174","author":"Olsen","year":"2021","journal-title":"Ann. Intern. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1001\/jama.2020.1585","article-title":"Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus\u2013Infected Pneumonia in Wuhan, China","volume":"323","author":"Wang","year":"2020","journal-title":"JAMA"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3389\/fmed.2020.00459","article-title":"COVID-19 Clinical Characteristics, and Sex-Specific Risk of Mortality: Systematic Review and Meta-Analysis","volume":"7","author":"Nasiri","year":"2020","journal-title":"Front. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e201","DOI":"10.1111\/bjh.16983","article-title":"Blood Cell Counts and Lymphocyte Subsets of Patients Admitted during the COVID-19 Pandemic: A Prospective Cohort Study","volume":"190","author":"Hengeveld","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_41","first-page":"323","article-title":"Effects of Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection on Peripheral Blood Lymphocytes and Their Subsets","volume":"9","author":"He","year":"2005","journal-title":"Int. J. Infect. Dis. IJID Off. Publ. Int. Soc. Infect. Dis."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"12762","DOI":"10.1038\/s41598-021-90983-0","article-title":"Baseline T-Lymphocyte Subset Absolute Counts Can Predict Both Outcome and Severity in SARS-CoV-2 Infected Patients: A Single Center Study","volume":"11","author":"Iannetta","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/S2213-2600(20)30404-5","article-title":"Cytokine Elevation in Severe and Critical COVID-19: A Rapid Systematic Review, Meta-Analysis, and Comparison with Other Inflammatory Syndromes","volume":"8","author":"Leisman","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"HLH Across Speciality Collaboration, UK COVID-19: Consider Cytokine Storm Syndromes and Immunosuppression","volume":"395","author":"Mehta","year":"2020","journal-title":"Lancet Lond. Engl."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/s41586-020-2355-0","article-title":"Viral and Host Factors Related to the Clinical Outcome of COVID-19","volume":"583","author":"Zhang","year":"2020","journal-title":"Nature"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"ofac027","DOI":"10.1093\/ofid\/ofac027","article-title":"Assessment of Virological Contributions to COVID-19 Outcomes in a Longitudinal Cohort of Hospitalized Adults","volume":"9","author":"Simons","year":"2022","journal-title":"Open Forum Infect. Dis."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"5493","DOI":"10.1038\/s41467-020-19057-5","article-title":"SARS-CoV-2 Viral Load Is Associated with Increased Disease Severity and Mortality","volume":"11","author":"Fajnzylber","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e4197","DOI":"10.1093\/cid\/ciaa851","article-title":"Impact of Severe Acute Respiratory Syndrome Coronavirus 2 Viral Load on Risk of Intubation and Mortality Among Hospitalized Patients With Coronavirus Disease 2019","volume":"73","author":"Magleby","year":"2021","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Knudtzen, F.C., Jensen, T.G., Lindvig, S.O., Rasmussen, L.D., Madsen, L.W., Hoegh, S.V., Bek-Thomsen, M., Laursen, C.B., Nielsen, S.L., and Johansen, I.S. (2021). SARS-CoV-2 Viral Load as a Predictor for Disease Severity in Outpatients and Hospitalised Patients with COVID-19: A Prospective Cohort Study. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0258421"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1186\/s13054-020-03244-3","article-title":"Nasopharyngeal Viral Load Predicts Hypoxemia and Disease Outcome in Admitted COVID-19 Patients","volume":"24","author":"Shlomai","year":"2020","journal-title":"Crit. Care"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Abdulrahman, A., Mallah, S.I., and Alqahtani, M. (2021). COVID-19 Viral Load Not Associated with Disease Severity: Findings from a Retrospective Cohort Study. BMC Infect. Dis., 21.","DOI":"10.1186\/s12879-021-06376-1"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1089\/vim.2020.0062","article-title":"Correlation Between Relative Nasopharyngeal Virus RNA Load and Lymphocyte Count Disease Severity in Patients with COVID-19","volume":"34","author":"Liu","year":"2021","journal-title":"Viral Immunol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"6385","DOI":"10.1038\/s41467-020-19761-2","article-title":"Treatment of COVID-19 with Remdesivir in the Absence of Humoral Immunity: A Case Report","volume":"11","author":"Buckland","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"ofab217","DOI":"10.1093\/ofid\/ofab217","article-title":"The Longest Persistence of Viable SARS-CoV-2 With Recurrence of Viremia and Relapsing Symptomatic COVID-19 in an Immunocompromised Patient\u2014A Case Study","volume":"8","author":"Sepulcri","year":"2021","journal-title":"Open Forum Infect. Dis."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"m1443","DOI":"10.1136\/bmj.m1443","article-title":"Viral Load Dynamics and Disease Severity in Patients Infected with SARS-CoV-2 in Zhejiang Province, China, January-March 2020: Retrospective Cohort Study","volume":"369","author":"Zheng","year":"2020","journal-title":"BMJ"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/S1473-3099(20)30232-2","article-title":"Viral Dynamics in Mild and Severe Cases of COVID-19","volume":"20","author":"Liu","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/s41586-020-2423-5","article-title":"Clinical Benefit of Remdesivir in Rhesus Macaques Infected with SARS-CoV-2","volume":"585","author":"Williamson","year":"2020","journal-title":"Nature"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Colagrossi, L., Antonello, M., Renica, S., Merli, M., Matarazzo, E., Travi, G., Vecchi, M., Colombo, J., Muscatello, A., and Grasselli, G. (2021). SARS-CoV-2 RNA in Plasma Samples of COVID-19 Affected Individuals: A Cross-Sectional Proof-of-Concept Study. BMC Infect. Dis., 21.","DOI":"10.1186\/s12879-021-05886-2"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/s12985-021-01638-5","article-title":"Circulating SARS-CoV-2 Variants in Italy, October 2020\u2013March 2021","volume":"18","author":"Lai","year":"2021","journal-title":"Virol. J."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Bozidis, P., Tsaousi, E.T., Kostoulas, C., Sakaloglou, P., Gouni, A., Koumpouli, D., Sakkas, H., Georgiou, I., and Gartzonika, K. (2022). Unusual N Gene Dropout and Ct Value Shift in Commercial Multiplex PCR Assays Caused by Mutated SARS-CoV-2 Strain. Diagn. Basel Switz., 12.","DOI":"10.3390\/diagnostics12040973"}],"container-title":["Microorganisms"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-2607\/11\/2\/312\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:15:23Z","timestamp":1760120123000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-2607\/11\/2\/312"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,25]]},"references-count":60,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["microorganisms11020312"],"URL":"https:\/\/doi.org\/10.3390\/microorganisms11020312","relation":{},"ISSN":["2076-2607"],"issn-type":[{"type":"electronic","value":"2076-2607"}],"subject":[],"published":{"date-parts":[[2023,1,25]]}}}